Two point estimates from one review indicated a significantly increased class association of bladder cancer with SGLT‐2 inhibitors (OR 3.87, 95%CI 1.48‐10.08 versus placebo and active comparators; OR 3.71, 95%CI 1.38‐9.96 vs placebo). Here, SLC5A2 is linked to urinary bladder carcinoma.